Casdatifan

Casdatifan is an investigational new drug that is being evaluated by Arcus Biosciences and AstraZeneca for the treatment of renal cell carcinoma. It is an inhibitor of endothelial PAS domain-containing protein 1 (HIF‑2α).
== Pharmacology == Casdatifan is allosteric HIF‑2α inhibitor with low-nanomolar potency in cell-based reporter assays.
== Clinical trials == Casdatifan in combination with cabozantinib (a tyrosine-kinase inhibitor) is currently in phase 3 clinical trials for the treatment of advanced clear cell renal cell carcinoma.
== References ==
Wikipedia contributors, "Casdatifan", Wikipedia, revision 1385112764, retrieved 21 November 2026, source, CC BY-SA 4.0.